combination therapy with glp-1 receptor agonist and sglt2 inhibitor Illustration of potential synergistic effects of Triple combination therapy may be

One 2017 study by John Hopkins Bloomberg School of Public Health suggested: Helping an adult lose weight leads to significant cost savings at any age. Mayo Clinic research from 2025 suggests that losing weight may reduce the risk of T2D

[DOI] [PMC free article] [PubMed] [Google Scholar] 57.Gwinner W., Landmesser U., Brandes R

As previously mentioned, patients with T2D on incretin-based therapies showed significant weight loss and improved glycemic control with little experience of hypoglycemia (47)

[53] Tirzepatide's efficacy for chronic weight management (weight reduction and maintenance) in combination with a reduced-calorie diet and increased physical activity was established in two randomized, double-blind, placebo-controlled trials in adults with obesity or overweight who had at least one weight-related condition

PATHOPHYSIOLOGY OF DKD Mechanisms of action SGLT2 inhibitors primarily act by blocking SGLT2 located on the luminal membranes of proximal renal tubules (S1 and S2 segments)

Nevertheless, GLP-1 RAs have gastrointestinal adverse effects such as abdominal pain, constipation, diarrhea, nausea, and vomiting [7]